Researchers studying over 2,000 Ashkenazi Jewish centenarians uncovered two rare IGF-1 gene variants linked to exceptional ...

Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form.

Scientists identify mutation patterns in healthy stomach lining, offering new insights into the earliest steps of cancer ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study.

The collaboration focuses on the development of the Lunit SCOPE Genotype Predictor, an AI-driven tool designed to rapidly and ...

Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form.

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

The study found that gastric cells in some individuals carried three copies of certain chromosomes, hinting toward exposure ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...